Pharmaceutical Technology Europe interviews Robert Wessman, Executive Chairman and a major shareholder of the Alvogen Group, and former CEO of generics company Actavis, on strategies for success in generics.
As with most others, the pharmaceutical industry is entering 2010 with trepidation; will this year bring a similar number of headline grabbing announcements of mergers and acquisitions, plant closures, job cuts, restructuring, etc.
It's customary among columnists to begin a new year with some predictions about what's to come. We don't honour that custom every year, but with what the contract services industry went through in 2009, it seemed appropriate to share thoughts on what we expect for 2010.
The free movement of goods across Europe might be beneficial for some, but for pharmaceutical companies, the parallel trade of medicines is not welcomed, and is viewed as a system that can damage patient safety and innovation
There is a pressing need to improve the storage stability of currently available vaccines, and achieving this could facilitate mass vaccination campaigns and increase vaccination coverage on a global scale — particularly to underserved and remote regions of the world.
Tumour-penetrating microparticles (TPM), drug delivery vehicles that have been designed to specifically target and infiltrate peritoneal tumours, are more efficacious than standard chemotherapy, according to our preliminary research data.